Cunha A M, Hagemann C C F, Simões R S, Oliveira-Filho R M, Simões M J, Soares J M, Maciel G A R, Oliveira F H M, Amed A A, Kulay L
Department of Obstetrics, Federal University of São Paulo, School of Medicine, S. Paulo, Brazil.
Eur J Obstet Gynecol Reprod Biol. 2007 Jul;133(1):60-3. doi: 10.1016/j.ejogrb.2006.08.004. Epub 2006 Sep 20.
To evaluate the biochemical and morphological effects in rats subjected to three different dose associations of the protease inhibitors lopinavir and ritonavir administered throughout the entire period of pregnancy.
The animals were treated throughout pregnancy with daily oral doses of lopinavir+ritonavir starting at the day one of pregnancy, and were divided into four groups: E1, 13.3+3.3 mg/kg; E2, 39.9+9.9 mg/kg; E3, 119.7+29.9 mg/kg and C, control (drug vehicle, propyleneglycol). The animals were then sacrificed and maternal blood and fetal and maternal organ samples were taken for morphological and biochemical analysis.
No major changes were identified in the group treated with the lowest dose as compared with the control. In the group E2, we found hepatocytes with signs of atrophy, eosinophilic cytoplasm, picnotic nuclei and vasodilatation. The proximal convoluted tubules of maternal kidneys showed eosinophilic areas and hyperchromatic nuclei, as well as signs of vasodilation. In the group treated with the highest dose (group E3), in the maternal kidneys and livers, the morphological changes were similar to those found in E2, although more prominent. Regarding the fetal organs, the single abnormality observed was some liver vasodilation in the group E3 (highest dose). The treatment with lopinavir+ritonavir caused discrete, yet significant, alterations of aspartate aminotransferase activity, blood urea nitrogen and creatinine plasma levels.
Our results showed that the administration of a combination of lopinavir plus ritonavir to pregnant rats can cause morphological as well as functional changes in maternal and fetal liver and kidneys and, in higher than therapeutic doses, might be toxic to those animals.
评估在整个孕期给予大鼠三种不同剂量组合的蛋白酶抑制剂洛匹那韦和利托那韦后的生化及形态学影响。
从妊娠第1天开始,在整个孕期每天给动物口服洛匹那韦+利托那韦,分为四组:E1组,13.3+3.3毫克/千克;E2组,39.9+9.9毫克/千克;E3组,119.7+29.9毫克/千克;C组为对照组(药物赋形剂,丙二醇)。然后处死动物,采集母血以及胎儿和母体器官样本进行形态学和生化分析。
与对照组相比,最低剂量治疗组未发现重大变化。在E2组,我们发现肝细胞有萎缩迹象、嗜酸性细胞质、固缩核和血管扩张。母体肾脏的近端曲管显示嗜酸性区域和核深染,以及血管扩张迹象。在最高剂量治疗组(E3组),母体肾脏和肝脏的形态学变化与E2组相似,但更为明显。关于胎儿器官,在E3组(最高剂量)观察到的唯一异常是一些肝脏血管扩张。洛匹那韦+利托那韦治疗导致天冬氨酸转氨酶活性、血尿素氮和血浆肌酐水平出现离散但显著的改变。
我们的结果表明,给怀孕大鼠施用洛匹那韦加利托那韦组合可导致母体和胎儿肝脏及肾脏出现形态学和功能变化,且高于治疗剂量时可能对这些动物有毒性。